Nath Bio-Genes (India) Ltd. (IN:NATHBIOGEN)
:NATHBIOGEN
NATHBIOGEN Stock Chart & Stats
₹158.80
-₹4.15(-2.25%)
At close: 4:00 PM EST
₹158.80
-₹4.15(-2.25%)
Day’s Range― - ―
52-Week Range₹126.75 - ₹238.00
Previous CloseN/A
Volume20.69K
Average Volume (3M)2.58K
Market Cap
₹2.84B
Enterprise Value₹4.38B
Total Cash (Recent Filing)₹1.59B
Total Debt (Recent Filing)₹1.55B
Price to Earnings (P/E)46.0
Beta1.16
Next Earnings
Jun 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.26%
Share Statistics
EPS (TTM)0.84
Shares Outstanding19,004,000
10 Day Avg. Volume2,256
30 Day Avg. Volume2,581
Financial Highlights & Ratios
PEG Ratio-3.00
Price to Book (P/B)0.47
Price to Sales (P/S)0.82
P/FCF Ratio31.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth (25% YoY) indicates expanding adoption of the company’s hybrid and improved seed portfolio across field crops. Durable top-line momentum supports reinvestment in R&D, scaling distribution, and helps smooth returns across seasonal cycles.
Profitability & MarginsConsistent gross and net margins imply the company captures value from seed pricing and cost structure. Margin stability enhances long-term cash generation, funds breeding programs and processing capacity, and provides resilience versus commodity input swings.
Balance Sheet StrengthA strong equity base and relatively low leverage give the company financial flexibility to finance seasonal working capital, fund seed multiplication cycles and capital investments without excessive refinancing risk, supporting long-term execution.
Bears Say
Cash Flow VariabilityVariable free cash flow conversion creates liquidity uncertainty across planting seasons. This can constrain timely investment in seed R&D, processing upgrades and working capital for peak sowing periods, making operations sensitive to collection and inventory timing.
Moderate Debt RelianceAlthough overall leverage appears reasonable, any moderate reliance on debt exposes the company to refinancing and interest-rate risk, especially given agricultural seasonality. Downturns or tighter credit could pressure liquidity and compel operational trade-offs.
Operating Margin VolatilityFluctuating operating margins point to sensitivity to input costs, pricing pressure and seasonal sales patterns. This variability can reduce predictability of earnings and complicate long-term planning for R&D spend, capacity expansion and dealer support programs.
Nath Bio-Genes (India) Ltd. News
NATHBIOGEN FAQ
What was Nath Bio-Genes (India) Ltd.’s price range in the past 12 months?
Nath Bio-Genes (India) Ltd. lowest stock price was ₹126.75 and its highest was ₹238.00 in the past 12 months.
What is Nath Bio-Genes (India) Ltd.’s market cap?
Nath Bio-Genes (India) Ltd.’s market cap is ₹2.84B.
When is Nath Bio-Genes (India) Ltd.’s upcoming earnings report date?
Nath Bio-Genes (India) Ltd.’s upcoming earnings report date is Jun 24, 2026 which is in 75 days.
How were Nath Bio-Genes (India) Ltd.’s earnings last quarter?
Nath Bio-Genes (India) Ltd. released its earnings results on Jan 31, 2026. The company reported ₹0.844 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.844.
Is Nath Bio-Genes (India) Ltd. overvalued?
According to Wall Street analysts Nath Bio-Genes (India) Ltd.’s price is currently Overvalued.
Does Nath Bio-Genes (India) Ltd. pay dividends?
Nath Bio-Genes (India) Ltd. pays a Notavailable dividend of ₹2 which represents an annual dividend yield of 1.26%. See more information on Nath Bio-Genes (India) Ltd. dividends here
What is Nath Bio-Genes (India) Ltd.’s EPS estimate?
Nath Bio-Genes (India) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nath Bio-Genes (India) Ltd. have?
Nath Bio-Genes (India) Ltd. has 19,004,000 shares outstanding.
What happened to Nath Bio-Genes (India) Ltd.’s price movement after its last earnings report?
Nath Bio-Genes (India) Ltd. reported an EPS of ₹0.844 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.843%.
Which hedge fund is a major shareholder of Nath Bio-Genes (India) Ltd.?
Currently, no hedge funds are holding shares in IN:NATHBIOGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nath Bio-Genes (India) Ltd.
Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers seeds for cereals, such as maize, paddy, millet, wheat, and jowar; fruit seeds; fiber and oil seeds, including cotton and mustard; and seeds for vegetables comprising chilli, okra, tomato, brinjal, bottle gourd, bitter gourd, sponge gourd, ridge gourd, cucumber, coriander, onion, sweet peeper, green paeas, pumpkin, tinda, cabbage, and French beans. It also provides crop protection supplements, such as WINPro GOLii, WINall, and Win Chi Win growth enhancer; and forage supplements, including NUTRIMAX GOLD and NUTRIMAX for enhanced fodder yields. The company offers its products through a network of distributors, dealers, and processing plants. Nath Bio-Genes (India) Limited was founded in 1979 and is based in Aurangabad, India.
Technical Analysis
Aries Agro Ltd.
―
Continental Seeds & Chemicals Ltd.
―
Goodricke Group Ltd
―
Harrisons Malayalam Ltd
―
Nova Agritech Limited
―